Abstract
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder in the world, and intracellular neurofibrillary tangles and extracellular amyloid-beta protein deposits represent the major pathological hallmarks of the disease. Currently available treatments provide some symptomatic relief but fail to modify primary pathological processes that underlie the disease. Erythropoietin (EPO), a hematopoietic growth factor, acts primarily to stimulate erythroid cell production, and is clinically used to treat anemia. EPO has evolved as a therapeutic agent for neurodegeneration and has improved neurological outcomes and AD pathology in rodents. However, penetration of the blood–brain barrier (BBB) and negative hematopoietic effects are the two major challenges for the therapeutic development of EPO for chronic neurodegenerative diseases like AD. The transferrin receptors at the BBB, which are responsible for transporting transferrin-bound iron from the blood into the brain parenchyma, can be used to shuttle therapeutic molecules across the BBB. In this review, we discuss the role of EPO as a potential neurotherapeutic for AD, challenges associated with EPO development for AD, and targeting the BBB transferrin receptor for EPO brain delivery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alzheimer's Association. (2018). Alzheimer’s disease facts and figures (2018). Alzheimer’s & Dementia, 14(3), 367–429. https://doi.org/10.1016/j.jalz.2018.02.001.
Arabpoor, Z., Hamidi, G., Rashidi, B., Shabrang, M., Alaei, H., Sharifi, M. R., et al. (2012). Erythropoietin improves neuronal proliferation in dentate gyrus of hippocampal formation in an animal model of Alzheimer’s disease. Advanced Biomedical Research. https://doi.org/10.4103/2277-9175.100157.
Ardura-Fabregat, A., Boddeke, E., Boza-Serrano, A., Brioschi, S., Castro-Gomez, S., Ceyzeriat, K., et al. (2017). Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs, 31(12), 1057–1082. https://doi.org/10.1007/s40263-017-0483-3.
Armand-Ugon, M., Aso, E., Moreno, J., Riera-Codina, M., Sanchez, A., Vegas, E., et al. (2015). Memory improvement in the AbetaPP/PS1 mouse model of familial Alzheimer’s disease induced by carbamylated-erythropoietin is accompanied by modulation of synaptic genes. Journal of Alzheimers Disease, 45(2), 407–421. https://doi.org/10.3233/jad-150002.
Assaraf, M. I., Diaz, Z., Liberman, A., Miller, W. H. Jr., Arvanitakis, Z., Li, Y., et al. (2007). Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. Journal of Neuropathology & Experimental Neurology, 66(5), 389–398. https://doi.org/10.1097/nen.0b013e3180517b28.
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017). Drugs in clinical trials for Alzheimer’s Disease: The major trends. Medicinal Research Reviews, 37(5), 1186–1225. https://doi.org/10.1002/med.21434.
Banks, W. A., Jumbe, N. L., Farrell, C. L., Niehoff, M. L., & Heatherington, A. C. (2004). Passage of erythropoietic agents across the blood-brain barrier: A comparison of human and murine erythropoietin and the analog darbepoetin alfa. European Journal of Pharmacology, 505(1–3), 93–101. https://doi.org/10.1016/j.ejphar.2004.10.035.
Barrett, A. M., Eslinger, P. J., Ballentine, N. H., & Heilman, K. M. (2005). Unawareness of cognitive deficit (cognitive anosognosia) in probable AD and control subjects. Neurology, 64(4), 693–699. https://doi.org/10.1212/01.wnl.0000151959.64379.1b.
Bartus, R. T., Dean, R. L. 3rd, Beer, B., & Lippa, A. S. (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217(4558), 408–414.
Bien-Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., et al. (2014). Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. Journal of Experimental Medicine, 211(2), 233–244. https://doi.org/10.1084/jem.20131660.
Boado, R. J., Hui, E. K., Lu, J. Z., & Pardridge, W. M. (2010). Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse. Journal of Pharmacology and Experimental Therapeutics, 333(3), 961–969. https://doi.org/10.1124/jpet.109.165092.
Boado, R. J., Zhang, Y., Wang, Y., & Pardridge, W. M. (2009). Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnology and Bioengineering, 102(4), 1251–1258. https://doi.org/10.1002/bit.22135.
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006). Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathology, 112(4), 389–404. https://doi.org/10.1007/s00401-006-0127-z.
Brettschneider, J., Widl, K., Ehrenreich, H., Riepe, M., & Tumani, H. (2006). Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases. Neuroscience Letters, 404(3), 347–351. https://doi.org/10.1016/j.neulet.2006.06.011.
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., et al. (2000). Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proceedings of the National Academy of Sciences of the United States of America, 97(19), 10526–10531.
Brunkan, A. L., & Goate, A. M. (2005). Presenilin function and gamma-secretase activity. Journal of Neurochemistry, 93(4), 769–792. https://doi.org/10.1111/j.1471-4159.2005.03099.x.
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., et al. (2011). Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Science Translational Medicine, 3(89), 89ra57. https://doi.org/10.1126/scitranslmed.3002156.
Chang, R., Maghribi, A., Vanderpoel, A., Vasilevko, V., Cribbs, V., Boado, D. H., R., et al (2018). Brain penetrating bifunctional erythropoietin-transferrin receptor antibody fusion protein for Alzheimer’s disease. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.8b00594.
Chow, V. W., Mattson, M. P., Wong, P. C., & Gleichmann, M. (2010). An overview of APP processing enzymes and products. Neuromolecular Medicine, 12(1), 1–12. https://doi.org/10.1007/s12017-009-8104-z.
Collin, L., Bohrmann, B., Gopfert, U., Oroszlan-Szovik, K., Ozmen, L., & Gruninger, F. (2014). Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer’s disease. Brain, 137(Pt 10), 2834–2846. https://doi.org/10.1093/brain/awu213.
Cornford, E. M., & Hyman, S. (2005). Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx, 2(1), 27–43. https://doi.org/10.1602/neurorx.2.1.27.
Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., et al. (2013). Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Science Translational Medicine, 5(183), 183ra157. https://doi.org/10.1126/scitranslmed.3005338. 181 – 112.
Danysz, W., Parsons, C. G., Mobius, H. J., Stoffler, A., & Quack, G. (2000). Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease—A unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research, 2(2–3), 85–97.
Dauphinot, V., Delphin-Combe, F., Mouchoux, C., Dorey, A., Bathsavanis, A., Makaroff, Z., et al. (2015). Risk factors of caregiver burden among patients with Alzheimer’s disease or related disorders: A cross-sectional study. Journal of Alzheimers Disease, 44(3), 907–916. https://doi.org/10.3233/jad-142337.
Dautry-Varsat, A., Ciechanover, A., & Lodish, H. F. (1983). pH and the recycling of transferrin during receptor-mediated endocytosis. Proceedings of the National Academy of Sciences of the United States of America, 80(8), 2258–2262.
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., et al. (2008). Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiology of Aging, 29(9), 1334–1347. https://doi.org/10.1016/j.neurobiolaging.2007.02.029.
DeKosky, S. T., & Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer’s disease: Correlation with cognitive severity. Annals of Neurology, 27(5), 457–464. https://doi.org/10.1002/ana.410270502.
Diaz, Z., Assaraf, M. I., Miller, W. H. Jr., & Schipper, H. M. (2005). Astroglial cytoprotection by erythropoietin pre-conditioning: Implications for ischemic and degenerative CNS disorders. Journal of Neurochemistry, 93(2), 392–402. https://doi.org/10.1111/j.1471-4159.2005.03038.x.
Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. A., Bauer, C., et al. (1995). Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proceedings of the National Academy of Sciences of the United States of America, 92(9), 3717–3720.
Dinamarca, M. C., Rios, J. A., & Inestrosa, N. C. (2012). Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer’s disease. Frontiers in Physiology, 3, 464. https://doi.org/10.3389/fphys.2012.00464.
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2013). A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. New England Journal of Medicine, 369(4), 341–350. https://doi.org/10.1056/NEJMoa1210951.
Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., et al. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology, 46(1), 136–150. https://doi.org/10.1007/s12035-012-8271-z.
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J., van Gool, W. A., & Hoozemans, J. J. (2006). The significance of neuroinflammation in understanding Alzheimer’s disease. Journal of Neural Transmission (Vienna), 113(11), 1685–1695. https://doi.org/10.1007/s00702-006-0575-6.
Erbayraktar, S., Grasso, G., Sfacteria, A., Xie, Q. W., Coleman, T., Kreilgaard, M., et al. (2003). Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 100(11), 6741–6746. https://doi.org/10.1073/pnas.1031753100.
Esmaeili Tazangi, P., Moosavi, S. M., Shabani, M., & Haghani, M. (2015). Erythropoietin improves synaptic plasticity and memory deficits by decrease of the neurotransmitter release probability in the rat model of Alzheimer’s disease. Pharmacology Biochemistry and Behavior, 130, 15–21. https://doi.org/10.1016/j.pbb.2014.12.011.
Fan, Z., Okello, A. A., Brooks, D. J., & Edison, P. (2015). Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease. Brain, 138(Pt 12), 3685–3698. https://doi.org/10.1093/brain/awv288.
Fishman, J. B., Rubin, J. B., Handrahan, J. V., Connor, J. R., & Fine, R. E. (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. Journal of Neuroscience Research, 18(2), 299–304. https://doi.org/10.1002/jnr.490180206.
Giannakopoulos, P., Duc, M., Gold, G., Hof, P. R., Michel, J. P., & Bouras, C. (1998). Pathologic correlates of apraxia in Alzheimer disease. Archives in Neurology, 55(5), 689–695.
Gremer, L., Scholzel, D., Schenk, C., Reinartz, E., & Labahn, J. (2017). Fibril structure of amyloid-beta(1–42) by cryo-electron microscopy. Science, 358(6359), 116–119, https://doi.org/10.1126/science.aao2825.
Haase, V. H. (2013). Regulation of erythropoiesis by hypoxia-inducible factors. Blood Review, 27(1), 41–53. https://doi.org/10.1016/j.blre.2012.12.003.
Haass, C., & De Strooper, B. (1999). The presenilins in Alzheimer’s disease–proteolysis holds the key. Science, 286(5441), 916–919.
Hardy, J. (2009). The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. Journal of Neurochemistry, 110(4), 1129–1134. https://doi.org/10.1111/j.1471-4159.2009.06181.x.
Hardy, J. A., & Higgins, G. A. (1992). Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256(5054), 184–185.
Hebert, L. E., Beckett, L. A., Scherr, P. A., & Evans, D. A. (2001). Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Disease and Associated Disorders, 15(4), 169–173.
Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G., Brosseron, F., Feinstein, D. L., et al. (2015). Neuroinflammation in Alzheimer’s disease. Lancet Neurology, 14(4), 388–405. https://doi.org/10.1016/s1474-4422(15)70016-5.
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 352(6286), 712–716. https://doi.org/10.1126/science.aad8373.
Hooshmandi, E., Motamedi, F., Moosavi, M., Katinger, H., Zakeri, Z., Zaringhalam, J., et al. (2018). CEPO-Fc (An EPO Derivative) protects hippocampus against abeta-induced memory deterioration: a behavioral and molecular study in a rat model of abeta toxicity. Neuroscience, 388, 405–417. https://doi.org/10.1016/j.neuroscience.2018.08.001.
Hultqvist, G., Syvanen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017). Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics, 7(2), 308–318. https://doi.org/10.7150/thno.17155.
Huwyler, J., & Pardridge, W. M. (1998). Examination of blood-brain barrier transferrin receptor by confocal fluorescent microscopy of unfixed isolated rat brain capillaries. Journal of Neurochemistry, 70(2), 883–886.
James, B. D., Leurgans, S. E., Hebert, L. E., Scherr, P. A., Yaffe, K., & Bennett, D. A. (2014). Contribution of Alzheimer disease to mortality in the United States. Neurology, 82(12), 1045–1050. https://doi.org/10.1212/wnl.0000000000000240.
Jefferies, W. A., Brandon, M. R., Hunt, S. V., Williams, A. F., Gatter, K. C., & Mason, D. Y. (1984). Transferrin receptor on endothelium of brain capillaries. Nature, 312(5990), 162–163.
Jelkmann, W. (2005). Effects of erythropoietin on brain function. Current Pharmaceutical Biotechnology, 6(1), 65–79.
Jelkmann, W. (2013). Physiology and pharmacology of erythropoietin. Transfusion Medicine and Hemotherapy, 40(5), 302–309. https://doi.org/10.1159/000356193.
Ji, P. (2016). Pericytes: new EPO-producing cells in the brain. Blood, 128(21), 2483–2485. https://doi.org/10.1182/blood-2016-10-743880.
Jiao, S. S., Shen, L. L., Zhu, C., Bu, X. L., Liu, Y. H., Liu, C. H., et al. (2016). Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Translational Psychiatry, 6(10), e907. https://doi.org/10.1038/tp.2016.186.
Jones, A. R., & Shusta, E. V. (2007). Blood-brain barrier transport of therapeutics via receptor-mediation. Pharmaceutical Research, 24(9), 1759–1771. https://doi.org/10.1007/s11095-007-9379-0.
Juul, S. E., Anderson, D. K., Li, Y., & Christensen, R. D. (1998). Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatrics Research, 43(1), 40–49. https://doi.org/10.1203/00006450-199804001-00243.
Kandimalla, R., & Reddy, P. H. (2017). Therapeutics of neurotransmitters in Alzheimer’s disease. Journal of Alzheimers Diseases, 57(4), 1049–1069. https://doi.org/10.3233/jad-161118.
Karch, C. M., & Goate, A. M. (2015). Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biological Psychiatry, 77(1), 43–51. https://doi.org/10.1016/j.biopsych.2014.05.006.
Kato, M., Miura, K., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y., et al. (1998). Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metabolism and Disposition, 26(2), 126–131.
King, V. R., Averill, S. A., Hewazy, D., Priestley, J. V., Torup, L., & Michael-Titus, A. T. (2007). Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. European Journal of Neuroscience, 26(1), 90–100. https://doi.org/10.1111/j.1460-9568.2007.05635.x.
Konishi, Y., Chui, D. H., Hirose, H., Kunishita, T., & Tabira, T. (1993). Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Research, 609(1–2), 29–35.
Konofagou, E. E., Tung, Y. S., Choi, J., Deffieux, T., Baseri, B., & Vlachos, F. (2012). Ultrasound-induced blood-brain barrier opening. Current Pharmaceutical Biotechnology, 13(7), 1332–1345.
Lapchak, P. A. (2010). Erythropoietin molecules to treat acute ischemic stroke: A translational dilemma! Expert Opinion on Investigational Drugs, 19(10), 1179–1186. https://doi.org/10.1517/13543784.2010.517954.
Lee, H. J., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000). Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. Journal of Pharmacology and Experimental Therapeutics, 292(3), 1048–1052.
Lee, S. T., Chu, K., Park, J. E., Jung, K. H., Jeon, D., Lim, J. Y., et al. (2012). Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer’s disease models. Journal of Neurochemistry, 120(1), 115–124. https://doi.org/10.1111/j.1471-4159.2011.07534.x.
Leuner, K., Muller, W. E., & Reichert, A. S. (2012). From mitochondrial dysfunction to amyloid beta formation: Novel insights into the pathogenesis of Alzheimer’s disease. Molecular Neurobiology, 46(1), 186–193. https://doi.org/10.1007/s12035-012-8307-4.
Li, G., Ma, R., Huang, C., Tang, Q., Fu, Q., Liu, H., et al. (2008). Protective effect of erythropoietin on beta-amyloid-induced PC12 cell death through antioxidant mechanisms. Neuroscience Letters, 442(2), 143–147. https://doi.org/10.1016/j.neulet.2008.07.007.
Li, J. Y., Boado, R. J., & Pardridge, W. M. (2001). Blood-brain barrier genomics. Journal of Cerebral Blood Flow & Metabolism, 21(1), 61–68. https://doi.org/10.1097/00004647-200101000-00008.
Li, Y. P., Yang, G. J., Jin, L., Yang, H. M., Chen, J., Chai, G. S., et al. (2015). Erythropoietin attenuates Alzheimer-like memory impairments and pathological changes induced by amyloid beta42 in mice. Brain Research, 1618, 159–167. https://doi.org/10.1016/j.brainres.2015.05.031.
Lochhead, J. J., & Thorne, R. G. (2012). Intranasal delivery of biologics to the central nervous system. Advanced Drug Delivery Reviews, 64(7), 614–628. https://doi.org/10.1016/j.addr.2011.11.002.
Lombardo, S., & Maskos, U. (2015). Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment. Neuropharmacology, 96(Pt B), 255–262, https://doi.org/10.1016/j.neuropharm.2014.11.018.
Lu, C. T., Zhao, Y. Z., Wong, H. L., Cai, J., Peng, L., & Tian, X. Q. (2014). Current approaches to enhance CNS delivery of drugs across the brain barriers. International Journal of Nanomedicine, 9, 2241–2257. https://doi.org/10.2147/ijn.s61288.
Lundby, C., Thomsen, J. J., Boushel, R., Koskolou, M., Warberg, J., Calbet, J. A., et al. (2007). Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. Journal of Physiology, 578(Pt 1), 309–314. https://doi.org/10.1113/jphysiol.2006.122689.
Ma, R., Xiong, N., Huang, C., Tang, Q., Hu, B., Xiang, J., et al. (2009). Erythropoietin protects PC12 cells from beta-amyloid(25–35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology, 56(6–7), 1027–1034. https://doi.org/10.1016/j.neuropharm.2009.02.006.
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U., Digicaylioglu, M., Henn, V., et al. (1996). Erythropoietin gene expression in human, monkey and murine brain. European Journal of Neuroscience, 8(4), 666–676.
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M., & Sasaki, R. (1994). A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. The Journal of Biological Chemistry, 269(30), 19488–19493.
Maurice, T., Mustafa, M. H., Desrumaux, C., Keller, E., Naert, G., de la García-Barceló, M. C., et al. (2013). Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Abeta(2)(5)(-)(3)(5) non-transgenic mouse model of Alzheimer’s disease. Journal of Psychopharmacology, 27(11), 1044–1057. https://doi.org/10.1177/0269881113494939.
Mawanda, F., & Wallace, R. (2013). Can infections cause Alzheimer’s disease? Epidemiologic Reviews, 35, 161–180. https://doi.org/10.1093/epirev/mxs007.
McGeer, E. G., & McGeer, P. L. (2003). Inflammatory processes in Alzheimer’s disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 27(5), 741–749. https://doi.org/10.1016/s0278-5846(03)00124-6.
Melov, S., Adlard, P. A., Morten, K., Johnson, F., Golden, T. R., Hinerfeld, D., et al. (2007). Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE, 2(6), e536. https://doi.org/10.1371/journal.pone.0000536.
Mennini, T., De Paola, M., Bigini, P., Mastrotto, C., Fumagalli, E., Barbera, S., et al. (2006). Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Molecular Medicine, 12(7–8), 153–160. https://doi.org/10.2119/2006-00045.Mennini.
Mitchell, S. L., Teno, J. M., Kiely, D. K., Shaffer, M. L., Jones, R. N., Prigerson, H. G., et al. (2009). The clinical course of advanced dementia. New England Journal of Medicine, 361(16), 1529–1538. https://doi.org/10.1056/NEJMoa0902234.
Moos, T., Nielsen, T. R., Skjorringe, T., & Morgan, E. H. (2007). Iron trafficking inside the brain. Journal of Neurochemistry, 103(5), 1730–1740. https://doi.org/10.1111/j.1471-4159.2007.04976.x.
Morishita, E., Masuda, S., Nagao, M., Yasuda, Y., & Sasaki, R. (1997). Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience, 76(1), 105–116.
Nagai, A., Nakagawa, E., Choi, H. B., Hatori, K., Kobayashi, S., & Kim, S. U. (2001). Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. Journal of Neuropathology & Experimental Neurology, 60(4), 386–392.
Ng, T., Marx, G., Littlewood, T., & Macdougall, I. (2003). Recombinant erythropoietin in clinical practice. Postgraduate Medical Journal, 79(933), 367–376.
Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nature Medicine, 9(4), 448–452. https://doi.org/10.1038/nm840.
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., et al. (2014). Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron, 81(1), 49–60. https://doi.org/10.1016/j.neuron.2013.10.061.
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., et al. (2012). Immunotherapy for Alzheimer’s disease: From anti-beta-amyloid to tau-based immunization strategies. Immunotherapy, 4(2), 213–238. https://doi.org/10.2217/imt.11.170.
Panza, F., Logroscino, G., Imbimbo, B. P., & Solfrizzi, V. (2014). Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Current Opinion in Psychiatry, 27(2), 128–137. https://doi.org/10.1097/yco.0000000000000041.
Pardridge, W. M. (2005). The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2(1), 3–14. https://doi.org/10.1602/neurorx.2.1.3.
Pardridge, W. M. (2006). Molecular Trojan horses for blood-brain barrier drug delivery. Discovery Medicine, 6(34), 139–143.
Pardridge, W. M. (2009). Alzheimer’s disease drug development and the problem of the blood-brain barrier. Alzheimers Dementia, 5(5), 427–432. https://doi.org/10.1016/j.jalz.2009.06.003.
Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. Journal of Cerebral Blood Flow & Metabolism, 32(11), 1959–1972. https://doi.org/10.1038/jcbfm.2012.126.
Pardridge, W. M. (2015). Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody. Expert Opinion on Drug Delivery, 12(2), 207–222. https://doi.org/10.1517/17425247.2014.952627.
Pardridge, W. M. (2016). CSF, blood-brain barrier, and brain drug delivery. Expert Opinion on Drug Delivery, 13(7), 963–975. https://doi.org/10.1517/17425247.2016.1171315.
Pardridge, W. M. (2017). Delivery of biologics across the blood-brain barrier with molecular Trojan horse technology. BioDrugs, 31(6), 503–519. https://doi.org/10.1007/s40259-017-0248-z.
Pardridge, W. M., Boado, R. J., Patrick, D. J., Ka-Wai Hui, E., & Lu, J. Z. (2018). Blood-brain barrier transport, plasma pharmacokinetics, and neuropathology following chronic treatment of the rhesus monkey with a brain penetrating humanized monoclonal antibody against the human transferrin receptor. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.8b00730.
Portet, F., Scarmeas, N., Cosentino, S., Helzner, E. P., & Stern, Y. (2009). Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study. Archive of Neurology, 66(9), 1120–1126. https://doi.org/10.1001/archneurol.2009.196.
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., et al. (2013). Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. Science Translational Medicine, 5(189), 189ra177. https://doi.org/10.1126/scitranslmed.3005615.
Preston, J. E., Abbott, N. J., & Begley, D. J. (2014). Transcytosis of macromolecules at the blood-brain barrier. Advances in Pharmacology, 71, 147–163. https://doi.org/10.1016/bs.apha.2014.06.001.
Priller, C., Bauer, T., Mitteregger, G., Krebs, B., Kretzschmar, H. A., & Herms, J. (2006). Synapse formation and function is modulated by the amyloid precursor protein. Journal of Neuroscience, 26(27), 7212–7221. https://doi.org/10.1523/jneurosci.1450-06.2006.
Reisberg, B., Doody, R., Stoffler, A., Schmitt, F., Ferris, S., & Mobius, H. J. (2003). Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine, 348(14), 1333–1341. https://doi.org/10.1056/NEJMoa013128.
Revett, T. J., Baker, G. B., Jhamandas, J., & Kar, S. (2013). Glutamate system, amyloid ss peptides and tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. Journal of Psychiatry Neurosci, 38(1), 6–23. https://doi.org/10.1503/jpn.110190.
Reynolds, G. P., Mason, S. L., Meldrum, A., De Keczer, S., Parnes, H., Eglen, R. M., et al. (1995). 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. British Journal of Pharmacology, 114(5), 993–998.
Roberts, R. L., Fine, R. E., & Sandra, A. (1993). Receptor-mediated endocytosis of transferrin at the blood-brain barrier. Journal of Cell Science, 104(Pt 2), 521–532.
Rodriguez Cruz, Y., Strehaiano, M., Obaya, R., Garcia Rodriguez, T., J. C., & Maurice, T. (2017). An intranasal formulation of erythropoietin (Neuro-EPO) prevents memory deficits and amyloid toxicity in the APPSwe transgenic mouse model of Alzheimer’s disease. Journal of Alzheimers Disease, 55(1), 231–248. https://doi.org/10.3233/jad-160500.
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., et al. (1995). Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature, 376(6543), 775–778. https://doi.org/10.1038/376775a0.
Rogers, J., Webster, S., Lue, L. F., Brachova, L., Civin, W. H., Emmerling, M., et al. (1996). Inflammation and Alzheimer’s disease pathogenesis. Neurobiology of Aging, 17(5), 681–686.
Sakanaka, M., Wen, T. C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., et al. (1998). In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A, 95(8), 4635–4640.
Samy, D. M., Ismail, C. A., Nassra, R. A., Zeitoun, T. M., & Nomair, A. M. (2016). Downstream modulation of extrinsic apoptotic pathway in streptozotocin-induced Alzheimer’s dementia in rats: Erythropoietin versus curcumin. European Journal of Pharmacology, 770, 52–60. https://doi.org/10.1016/j.ejphar.2015.11.046.
Sarazin, M., Stern, Y., Berr, C., Riba, A., Albert, M., Brandt, J., et al. (2005). Neuropsychological predictors of dependency in patients with Alzheimer disease. Neurology, 64(6), 1027–1031. https://doi.org/10.1212/01.wnl.0000154529.53488.30.
Sargin, D., Friedrichs, H., El-Kordi, A., & Ehrenreich, H. (2010). Erythropoietin as neuroprotective and neuroregenerative treatment strategy: Comprehensive overview of 12 years of preclinical and clinical research. Best Practice & Research: Clinical Anaesthesiology, 24(4), 573–594. https://doi.org/10.1016/j.bpa.2010.10.005.
Schupf, N., Kapell, D., Nightingale, B., Rodriguez, A., Tycko, B., & Mayeux, R. (1998). Earlier onset of Alzheimer’s disease in men with Down syndrome. Neurology, 50(4), 991–995.
Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2011). Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Current Neurovascular Research, 8(4), 270–285.
Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2012). Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY), 4(3), 187–201. https://doi.org/10.18632/aging.100440.
Sigurdsson, E. M. (2018). Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls. Journal of Alzheimers Disease, 64(s1), S555–Ss565. https://doi.org/10.3233/jad-179937.
Slotkin, T. A., Seidler, F. J., Crain, B. J., Bell, J. M., Bissette, G., & Nemeroff, C. B. (1990). Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. Proceedings of the National Academy of Sciences of the United States of America, 87(7), 2452–2455.
Sosa-Ortiz, A. L., Acosta-Castillo, I., & Prince, M. J. (2012). Epidemiology of dementias and Alzheimer’s disease. Archives of Medical Research, 43(8), 600–608. https://doi.org/10.1016/j.arcmed.2012.11.003.
Thal, D. R., Rub, U., Orantes, M., & Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology, 58(12), 1791–1800.
Torup, L., & Leist, M. (2006). Development of non-erythropoietic erythropoietin variants for neuroprotection. In A. Höke (Ed.), Erythropoietin and the nervous system: novel therapeutic options for neuroprotection (pp. 211–219). Boston: Springer.
Ulrich, D. (2015). Amyloid-beta Impairs synaptic inhibition via GABA(A) receptor endocytosis. Journal of Neuroscience, 35(24), 9205–9210. https://doi.org/10.1523/jneurosci.0950-15.2015.
van Marum, R. J. (2009). Update on the use of memantine in Alzheimer’s disease. Neuropsychiatric Disease and Treatment, 5, 237–247.
Villa, P., Bigini, P., Mennini, T., Agnello, D., Laragione, T., Cagnotto, A., et al. (2003). Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Journal of Experimental Medicine, 198(6), 971–975. https://doi.org/10.1084/jem.20021067.
Viviani, B., Bartesaghi, S., Corsini, E., Villa, P., Ghezzi, P., Garau, A., et al. (2005). Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor. Journal of Neurochemistry, 93(2), 412–421. https://doi.org/10.1111/j.1471-4159.2005.03033.x.
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017). Epileptic activity in Alzheimer’s disease: Causes and clinical relevance. Lancet Neurology, 16(4), 311–322. https://doi.org/10.1016/s1474-4422(17)30044-3.
Wan, H. I., Jacobsen, J. S., Rutkowski, J. L., & Feuerstein, G. Z. (2009). Translational medicine lessons from flurizan’s failure in Alzheimer’s disease (AD) trial: Implication for future drug discovery and development for AD. Clinical and Translational Science, 2(3), 242–247. https://doi.org/10.1111/j.1752-8062.2009.00121.x.
Wang, W. Y., Tan, M. S., Yu, J. T., & Tan, L. (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Annals of Translational Medicine, 3(10), 136. https://doi.org/10.3978/j.issn.2305-5839.2015.03.49.
Weber, F., Bohrmann, B., Niewoehner, J., Fischer, J. A. A., Rueger, P., Tiefenthaler, G., et al. (2018). Brain Shuttle antibody for Alzheimer’s disease with attenuated peripheral effector function due to an inverted binding mode. Cell Reports, 22(1), 149–162. https://doi.org/10.1016/j.celrep.2017.12.019.
Wenk, G. L. (2003). Neuropathologic changes in Alzheimer’s disease. Journal of Clinical Psychiatry, 64(Suppl 9), 7–10.
Wenker, S. D., Chamorro, M. E., Vittori, D. C., & Nesse, A. B. (2013). Protective action of erythropoietin on neuronal damage induced by activated microglia. FEBS J, 280(7), 1630–1642. https://doi.org/10.1111/febs.12172.
Wildburger, N. C., Esparza, T. J., & LeDuc, R. D. (2017). Diversity of Amyloid-beta Proteoforms in the Alzheimer’s Disease Brain. Scientific Reports, 7(1), 9520, https://doi.org/10.1038/s41598-017-10422-x.
Wyss-Coray, T. (2006). Inflammation in Alzheimer disease: Driving force, bystander or beneficial response? Nature Medicine, 12(9), 1005–1015. https://doi.org/10.1038/nm1484.
Yu, Y. J., Atwal, J. K., Zhang, Y., Tong, R. K., Wildsmith, K. R., Tan, C., et al. (2014). Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Science Translational Medicine, 6(261), 261ra154. https://doi.org/10.1126/scitranslmed.3009835.
Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Science Translational Medicine, 3(84), 84ra44. https://doi.org/10.1126/scitranslmed.3002230.
Zhang, Y., & Pardridge, W. M. (2001). Rapid transferrin efflux from brain to blood across the blood-brain barrier. Journal of Neurochemistry, 76(5), 1597–1600.
Zhang, Z., Song, M., Liu, X., Kang, S. S., Kwon, I. S., Duong, D. M., et al. (2014). Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease. Nature Medicine, 20(11), 1254–1262. https://doi.org/10.1038/nm.3700.
Zhou, Q. H., Boado, R. J., Lu, J. Z., Hui, E. K., & Pardridge, W. M. (2010). Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse. Molecular Pharmaceutics, 7(6), 2148–2155. https://doi.org/10.1021/mp1001763.
Zhou, Q. H., Hui, E. K., Lu, J. Z., Boado, R. J., & Pardridge, W. M. (2011). Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson’s disease in the mouse. Brain Research, 1382, 315–320. https://doi.org/10.1016/j.brainres.2011.01.061.
Acknowledgements
This work was supported by a Grant from The National Institute of Health, NIA R21AG055949 (to RKS).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sun, J., Martin, J.M., Vanderpoel, V. et al. The Promises and Challenges of Erythropoietin for Treatment of Alzheimer’s Disease. Neuromol Med 21, 12–24 (2019). https://doi.org/10.1007/s12017-019-08524-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12017-019-08524-y